| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
2,646 | 2,968 | 3,318 | 10,153 | 4,350 | 3,423 | 2,386 |
Operating expenses: | ||||||
Research and development, net | ||||||
7,917 | 11,994 | 7,053 | 7,269 | 7,324 | 3,969 | 4,225 |
General and administrative | ||||||
4,191 | 1,791 | 3,881 | 3,456 | 3,534 | 3,810 | 8,233 |
Total operating expenses | ||||||
12,108 | 13,785 | 10,934 | 10,725 | 10,858 | 7,779 | 12,458 |
Loss from operations | ||||||
-9,462 | -10,817 | -7,616 | -572 | -6,508 | -4,356 | -10,072 |
Loss from equity-method investment | ||||||
-163 | -47 | 303 | 0 | -288 | -47 | -47 |
Finance expense, net | ||||||
-152 | -125 | -120 | -113 | -88 | 150 | 169 |
Net loss | ||||||
-9,777 | -10,989 | -7,433 | -685 | -6,884 | -4,253 | -9,950 |
Net loss per share, basic and diluted | ||||||
-0.67 | -0.84 | -0.56 | -0.07 | -0.68 | -0.42 | -0.99 |
Weighted-average shares outstanding, basic and diluted | ||||||
14,521 | 14,568 | 13,201 | 10,412 | 10,095 | 10,093 | 10,057 |
Comprehensive loss: | ||||||
Net loss | ||||||
-9,777 | -10,989 | -7,433 | -685 | -6,884 | -4,253 | -9,950 |
Unrealized gain on short-term investments | ||||||
- | - | - | - | - | 2 | 7 |
Comprehensive loss | ||||||
-9,777 | -10,989 | -7,433 | -685 | -6,884 | -4,251 | -9,943 |